On October 27, 2015 Verastem, Inc. (NASDAQ:VSTM) reported four poster presentations at the 2015 AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) being held November 5-9, 2015 in Boston, Massachusetts (Press release, Verastem, OCT 27, 2015, View Source;p=RssLanding&cat=news&id=2102659 [SID:1234507807]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The details for the poster presentations at AACR (Free AACR Whitepaper)-NCI-EORTC are as follows:

Title: FAK/PYK2 Inhibitors Defactinib and VS-4718 Enhance Immune Checkpoint Inhibitor Efficacy
Date and time: Friday, November 6 from 12:15 – 3:15 pm
Location: Exhibit Hall C-D
Session info: Tumor Immunology Targets
Abstract ID: A191

Title: Focal Adhesion Kinase Inhibition Enables Efficacy of Checkpoint Immunotherapy in Pancreatic Cancer
Date and time: Saturday, November 7 from 12:30 – 3:30 pm
Location: Exhibit Hall C-D
Session info: Tumor Microenvironment
Abstract ID: B197

Title: FAK Inhibition Induces T Cell-mediated Tumor Regression: A Novel Role for Nuclear FAK in Controlling Tregs via Transcription of Cytokine Networks
Date and time: Friday November 6, 2015 12:15 PM – 3:15 PM
Location: Exhibit Hall C-D
Session info: Tumor Immunology Targets
Abstract ID: A189

Title: FAK Inhibition Targets Cancer Stem Cells
Date and time: Sunday November 8, 2015 12:30 PM – 3:30 PM
Location: Exhibit Hall C-D
Session info: Cancer Stem Cells
Abstract ID: C29

About VS-6063
VS-6063 (defactinib) is an orally available compound designed to target cancer stem cells through the potent inhibition of focal adhesion kinase (FAK). Cancer stem cells are an underlying cause of tumor resistance to chemotherapy, recurrence and ultimate disease progression. Research has demonstrated that FAK activity is critical for the growth and survival of cancer stem cells. VS-6063 is currently being studied in the "Window of Opportunity" study in patients with mesothelioma prior to surgery, a Phase 1/1b study in combination with paclitaxel in patients with ovarian cancer, a trial in patients with KRAS-mutated non-small cell lung cancer and a trial evaluating the combination of VS-6063 and VS-5584 in patients with relapsed mesothelioma.

About VS-4718
VS-4718 is an orally available compound designed to target cancer stem cells through the potent inhibition of focal adhesion kinase (FAK). VS-4718 is currently being studied in a Phase 1 dose escalation study in patients with advanced cancers.